Cardinal Health stock reacts to dividend and analyst shift

Cardinal Health stock (ISIN US14149Y1082) traded at USD 224.95 on the New York Stock Exchange as of September 18, 2026, leaving the shares about 13 percent below their 12-month high of USD 258.30 and setting the stage for a fresh look at the company’s fundamentals and analyst sentiment.

Dividend and recent price action

According to Ad-hoc-news on September 18, 2026, Cardinal Health stock previously closed at USD 240.49 on September 17, 2026, a decline of USD 6.69 or 2.71 percent in that session on the New York Stock Exchange.

The same overview reports that Cardinal Health announced a cash dividend of USD 0.516 per share with an ex-dividend date set for October 1, 2026, signaling continued cash returns for shareholders even as the stock consolidates after a strong run over the past year.

For investors, the recent pullback from USD 240.49 to USD 224.95 between September 17 and September 18, 2026 highlights how dividend distributions and shifting expectations can interact with broader market volatility, especially with the shares still trading meaningfully below their 12-month high of USD 258.30.

Earnings beat and analyst consensus

As MarketBeat reported on September 19, 2026, Cardinal Health recently delivered quarterly earnings per share of USD 2.91, clearly above analyst estimates of USD 2.42 for the period.

In the same note, MarketBeat points out that quarterly revenue rose 5.8 percent year over year to USD 63.67 billion, although this figure fell short of market expectations for the period.

For investors, that combination of an earnings beat alongside a revenue shortfall explains part of the market’s more cautious stance, with strong profitability but a reminder that top-line growth remains under close scrutiny in the current environment.

According to the analyst overview on MarketBeat dated September 19, 2026, Cardinal Health carries a consensus rating of Moderate Buy based on 16 Buy recommendations and 3 Hold ratings.

The same overview cites an average analyst price target of USD 266.56, implying upside of about 18.5 percent from the USD 224.95 share price, which frames current expectations for further gains if execution and market conditions remain supportive.

In a more nuanced signal, MarketBeat notes that research platform Wall Street Zen shifted its view on Cardinal Health from a strong-buy rating to a buy rating in a note dated September 19, 2026, a change that still reflects a positive stance but suggests less aggressive upside conviction than before.

Valuation, trading range and risks

Per the stock snapshot on MarketBeat, Cardinal Health shares closed at USD 224.95 on September 18, 2026, down 0.61 percent on the day, with an indicated market capitalization of USD 52.32 billion at that level.

The same overview lists a 12-month low of USD 145.87 and a 12-month high of USD 258.30, giving investors a sense of the substantial range the stock has traversed over the past year and placing the current price roughly midway between those extremes but still well above the low.

At the USD 224.95 share price, MarketBeat calculates a price-earnings ratio of 31.11 and a dividend yield of 0.92 percent, underscoring that the market is willing to pay a premium multiple for Cardinal Health’s earnings stream while the cash yield remains relatively modest.

For investors comparing the current position to the start of the year, MarketBeat notes that Cardinal Health’s stock traded at USD 205.62 at the beginning of 2026 and has since risen by 9.4 percent to USD 224.95, a gain that trails some higher-growth peers but still represents a solid positive return.

In its analyst commentary, MarketBeat also highlights insider activity, stating that insiders have sold approximately USD 49.6 million worth of Cardinal Health shares over the past 90 days, a factor some investors may view as a short-term risk signal despite the overall Moderate Buy consensus.

Stock snapshot and trading venue

Cardinal Health stock is listed on the New York Stock Exchange under the ticker symbol CAH, and the reference price in this article is the regular-session close of USD 224.95 in United States dollars on September 18, 2026.

With the shares currently about 18.5 percent below the average analyst price target of USD 266.56 and trading between the 12-month low of USD 145.87 and the 12-month high of USD 258.30, the stock offers investors a blend of earnings momentum, dividend income and valuation premium, all of which will be tested as the company approaches its next ex-dividend date on October 1, 2026.

More news and analyses on Cardinal Health stock